← back to search

Katherine A. Collins

Icahn School of Medicine at Mount Sinai · US
Area of research
Pharmacology · Experimental and Cognitive Psychology
Research interest
Research interests include Medicine, Psychology, Ketamine, Treatment-resistant depression, Major depressive disorder, and Depression (economics).
h-index
citations
3,360
works
23
NIH funding
primary concept
email

Recent publications

Molecular Transducers of Physical Activity Consortium (MoTrPAC): human studies design and protocol
Journal of Applied Physiology 2024cited by 19position: middledoi
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
New England Journal of Medicine 2023cited by 244position: middledoi
Very Low-Level Transcranial Photobiomodulation for Major Depressive Disorder
The Journal of Clinical Psychiatry 2022cited by 34position: middledoi
Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia
Translational Psychiatry 2021cited by 86position: middledoi
Interoception and Obsessive-Compulsive Disorder: A Review of Current Evidence and Future Directions
Frontiers in Psychiatry 2021cited by 25position: middledoi
Affective and somatic symptom clusters in depression and their relationship to treatment outcomes in the STAR*D sample
Journal of Affective Disorders 2021cited by 14position: firstdoi
Dimensions of interoception in obsessive-compulsive disorder
Journal of Obsessive-Compulsive and Related Disorders 2020cited by 24position: middledoi
Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial
Neuropsychopharmacology 2019cited by 51position: middledoi
Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression
Chronic Stress 2019cited by 13position: middledoi
Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder
Molecular Psychiatry 2018cited by 76position: middledoi
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol
Contemporary Clinical Trials 2018cited by 54position: middledoi
A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo
Journal of Affective Disorders 2018cited by 53position: middledoi
A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression
npj Digital Medicine 2018cited by 37position: middledoi
A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder
The International Journal of Neuropsychopharmacology 2017cited by 78position: middledoi
Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial
Journal of Affective Disorders 2017cited by 62position: middledoi
Ketamine Treatment and Global Brain Connectivity in Major Depression
Neuropsychopharmacology 2016cited by 302position: middledoi
Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder
Human Brain Mapping 2016cited by 159position: middledoi
Using Placebo Response to Pain as a Predictor of Placebo Response in Mood Disorders
Current Behavioral Neuroscience Reports 2016cited by 1position: middledoi
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
Psychological Medicine 2015cited by 294position: middledoi
Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response
Psychopharmacology 2013cited by 108position: middledoi
Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients
Gynecologic Oncology 2013cited by 24position: middledoi
Paraneoplastic Thrombocytosis in Ovarian Cancer
New England Journal of Medicine 2012cited by 822position: middledoi
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
Biological Psychiatry 2012cited by 780position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Dan V. Iosifescu · Psychiatric Medical Center16 papers (2012–2022)James W. Murrough · Center for Anxiety and Depression15 papers (2012–2023)Dennis S. Charney · Riverkeeper10 papers (2012–2019) · 6 papers (2016–2023)Brian M. Iacoviello · Icahn School of Medicine at Mount Sinai6 papers (2013–2019)Emily Stern · Nathan Kline Institute for Psychiatric Research4 papers (2020–2021)Sanjay J. Mathew · Baylor College of Medicine4 papers (2012–2023)Kaitlin E. DeWilde · Albert Einstein College of Medicine4 papers (2015–2019)Jaclyn Schwartz · Stanford University3 papers (2016–2019)Laili Soleimani · Alzheimer’s Disease Neuroimaging Initiative3 papers (2015–2019) · 3 papers (2018–2019)Marin Kautz · California University of Pennsylvania3 papers (2015–2018)Andrew M. Perez · University of Central Florida3 papers (2012–2015)Goi Khia Eng · New York University3 papers (2020–2021)Michael K. Parides · Hospital for Special Surgery3 papers (2012–2021)Adriana Feder · Icahn School of Medicine at Mount Sinai2 papers (2017–2019) · 2 papers (2018–2019)Jessica Stern · Icahn School of Medicine at Mount Sinai2 papers (2012–2015) · 2 papers (2018–2023)Alan Anticevic · Johnson & Johnson (United States)2 papers (2016–2016)